Trial Profile
A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hypervolemic Cirrhotic Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Conivaptan (Primary)
- Indications Liver cirrhosis
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 10 May 2014 New trial record